Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report

Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) may achieve long-term survival in selected cases with advanced non-small cell lung cancer harboring activating mutations in the EGFR gene, but a cured case has not been reported yet. Here, we present the first case of E...

Cijeli opis

Bibliografski detalji
Glavni autori: Taiji Kuwata, Kazue Yoneda, Kenichi Kobayashi, Rintarou Oyama, Hiroki Matumiya, Shuichi Shinohara, Masaru Takenaka, Soichi Oka, Yasuhiro Chikaishi, Naoko Imanishi, Koji Kuroda, Fumihiro Tanaka
Format: Članak
Jezik:English
Izdano: Karger Publishers 2016-10-01
Serija:Case Reports in Oncology
Teme:
Lung cancer
EGFR mutation
EGFR TKI
Online pristup:http://www.karger.com/Article/FullText/449371

Internet

http://www.karger.com/Article/FullText/449371

Slični predmeti